

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/895,843	BECK ET AL.	
	<b>Examiner</b>	Art Unit	
	Sudhaker B. Patel, D.Sc.Tech.	1624	

-- **The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 11/21/03.
2.  The allowed claim(s) is/are 104-108, 110-124, 130-138, 146, 148-150, 158-161, 168-171 and 176-206.
3.  The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All    b)  Some\*    c)  None    of the:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_ .
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached  
1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of  
Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review ( PTO-948)
3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date 10/02 & 7/04.
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application (PTO-152)
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

## REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:
2. Applicants' communication paper dated 7/2/04 is acknowledged.
3. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 7/2/04 has been entered.
4. Signed copies of the IDS paper(s) submitted on 7/22/01 and 7/2/04 are enclosed with this communication for applicants' record.
5. As per applicants' earlier communication paper dated 11/14/03, applicants have cancelled claims 1-103, 109, 125-129, 139-145, 147, 151-157, 162-167, 172-175, amended claims 104, 110, 116, 122, 130, 132, 146, 148, 160, 168, and presented new claims 176-206. Therefore, claims under consideration are the claims 104-108, 110-124, 130-138, 146, 148-150, 158-161, 168-171, 176-206. These claims are renumbered as claims 1-72.
6. The closest prior art of record reference Dressman et al (WO 9509843 also cited as CAS abstract # 123:169523-1995:772556) teaches making of HIV protease inhibitor(s) (see compound on page 39 lines 9-12) with a core:
7. "Substituted phenol-CO-NH-CH (CH<sub>2</sub>-S-Ph)-CH (OH)-CH<sub>2</sub>-piperazine-N-CH<sub>2</sub>-pyridine, wherein piperazine is further substituted on ring carbon atom with—CO-NH-alkyl group".
8. The ref. '843 differs from the instant claims by not having piperidine N substituted as —N-alkyl group, and additionally, by having 1,4-piperazine substituted by —CO-NH-alkyl group.
9. Dressman does not indicate or suggest arriving at the instant compounds with a core: ". Substituted 1,3-Benzenedicarboxamide with 3-position occupied by --CO-NH-CH (CH<sub>2</sub> diflouro-Ph)-CH (OH)-CH<sub>2</sub>-piperazine-N-CH<sub>3</sub>".
10. Therefore the instant compounds of invention of Group IX are deemed to be novel and patentably distinct.
11. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671.

13. The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James O. Wilson at (571) 272-0661.

14. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.

15. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Sudhaker B. Patel, D.Sc. Tech.  
August 11, 2004

  
RICHARD L. RAYMOND  
PRIMARY EXAMINER  
MUKUND J. SHAH  
ART UNIT 1624  
SUPERVISORY PATENT  
EXAMINER  
ART UNIT 1624/1623